Baker Bros. Advisors as of June 30, 2012
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 68 positions in its portfolio as reported in the June 2012 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
38 Seattle Genetics | 8.0 | $91M | 19M | 4.69 | |
Genomic Health | 6.5 | $74M | 11M | 6.62 | |
Viropharma | 6.0 | $69M | 11M | 6.06 | |
Auxilium | 6.0 | $68M | 6.3M | 10.90 | |
60 Salix 2.75% 5/15/15 conv bonds | 4.4 | $50M | 111M | 0.45 | |
Biomarin Pharmaceutical Inc note 1.875% 4/2 | 4.1 | $47M | 23M | 2.04 | |
XOMA CORP Common equity shares | 4.1 | $46M | 16M | 2.98 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 4.0 | $45M | 811k | 55.92 | |
Medivation | 3.9 | $44M | 483k | 91.40 | |
Spectrum Pharmaceuticals | 3.4 | $39M | 2.5M | 15.56 | |
Gilead Sciences (GILD) | 3.3 | $38M | 740k | 51.28 | |
61 Salix 144a 1.5% 3/15/19 conv bonds | 3.3 | $38M | 222M | 0.17 | |
Intermune cv 5.0% | 3.2 | $37M | 34M | 1.08 | |
31 Incyte | 3.2 | $36M | 15M | 2.44 | |
59 Salix 5.5% 8/15/28 conv bonds | 2.9 | $33M | 22M | 1.46 | |
Medivation Inc note 2.625% 4/0 | 2.6 | $29M | 25M | 1.19 | |
Gilead Sciences conv | 2.5 | $28M | 22M | 1.30 | |
Clovis Oncology | 2.2 | $25M | 1.2M | 21.68 | |
37 Pharmacyclics | 2.2 | $25M | 11M | 2.18 | |
BioCryst Pharmaceuticals (BCRX) | 1.9 | $22M | 5.6M | 3.97 | |
61 Incyte Genomics Notes 4.75% 10/1/2015 conv bonds | 1.5 | $17M | 158M | 0.11 | |
Intermune Inc note 2.500% 9/1 | 1.5 | $17M | 22M | 0.80 | |
Threshold Pharma | 1.5 | $17M | 2.2M | 7.40 | |
Vertex Pharmaceuticals Inc note 3.350%10/0 | 1.4 | $16M | 13M | 1.30 | |
D Tranzyme | 1.3 | $15M | 3.8M | 3.76 | |
Onyx Pharmaceuticals | 1.2 | $14M | 215k | 66.45 | |
Halozyme Therapeutics (HALO) | 1.0 | $12M | 1.3M | 8.86 | |
Ym Biosciences | 1.0 | $12M | 5.9M | 1.99 | |
BioDelivery Sciences International | 1.0 | $12M | 2.6M | 4.48 | |
Derma Sciences | 1.0 | $12M | 1.2M | 9.52 | |
Exelixis (EXEL) | 1.0 | $11M | 2.0M | 5.53 | |
ACADIA Pharmaceuticals (ACAD) | 0.8 | $9.2M | 5.2M | 1.76 | |
Aegerion Pharmaceuticals | 0.8 | $9.1M | 615k | 14.84 | |
BioMarin Pharmaceutical (BMRN) | 0.7 | $7.9M | 200k | 39.58 | |
Synergy Pharmaceuticals | 0.5 | $5.3M | 1.1M | 4.75 | |
XenoPort | 0.4 | $4.9M | 809k | 6.04 | |
Chelsea Therapeutics International | 0.4 | $4.5M | 3.0M | 1.48 | |
Cerus Corporation (CERS) | 0.4 | $4.2M | 1.3M | 3.32 | |
Amicus Therapeutics (FOLD) | 0.4 | $4.2M | 765k | 5.50 | |
Alere Inc note 3.000% 5/1 | 0.4 | $4.0M | 4.5M | 0.90 | |
Anacor Pharmaceuticals | 0.3 | $3.7M | 568k | 6.49 | |
Array BioPharma | 0.3 | $3.5M | 1.0M | 3.47 | |
Repros Therapeutics | 0.3 | $3.5M | 385k | 9.08 | |
Alere | 0.3 | $3.4M | 175k | 19.44 | |
45 Synageva Biopharma | 0.3 | $3.3M | 7.5M | 0.44 | |
Qlt | 0.2 | $2.7M | 352k | 7.62 | |
Sequenom | 0.2 | $2.4M | 588k | 4.06 | |
ZIOPHARM Oncology | 0.2 | $2.4M | 400k | 5.95 | |
Discovery Laboratories | 0.2 | $2.4M | 1.0M | 2.32 | |
AVEO Pharmaceuticals | 0.2 | $2.1M | 171k | 12.16 | |
INC Ventrus Biosciences | 0.2 | $2.1M | 481k | 4.27 | |
AVANIR Pharmaceuticals | 0.2 | $2.0M | 500k | 3.92 | |
32 Infinity Pharmaceuticals | 0.2 | $1.9M | 138k | 13.56 | |
Synta Pharmaceuticals | 0.1 | $1.7M | 313k | 5.47 | |
Targacept | 0.1 | $1.7M | 407k | 4.30 | |
Biodel | 0.1 | $1.4M | 540k | 2.58 | |
Ligand Pharmaceuticals | 0.1 | $1.2M | 73k | 16.93 | |
Rigel Pharmaceuticals | 0.1 | $920k | 99k | 9.30 | |
Anthera Pharmaceuticals | 0.1 | $815k | 1.2M | 0.68 | |
Chemocentryx | 0.1 | $750k | 50k | 15.00 | |
Raptor Pharmaceutical | 0.1 | $558k | 100k | 5.58 | |
ArQule | 0.0 | $511k | 86k | 5.93 | |
Idera Pharmaceuticals | 0.0 | $306k | 288k | 1.06 | |
Cubist Pharmaceuticals | 0.0 | $190k | 5.0k | 38.00 | |
9 Ariad Pharmaceuticals | 0.0 | $175k | 5.8M | 0.03 | |
Cumberland Pharmaceuticals (CPIX) | 0.0 | $153k | 24k | 6.48 | |
Cyclacel Pharmaceuticals Inc pfd conv ex 6% (CYCCP) | 0.0 | $52k | 21k | 2.48 | |
Aradigm Corporation (ARDM) | 0.0 | $12k | 100k | 0.12 |